Frazier Life Sciences Acquisition Corp. II’s (NASDAQ:FLSC) Quiet Period Set To End Tomorrow

Frazier Life Sciences Acquisition Corp. II’s (NASDAQ:FLSC – Get Free Report) quiet period will end on Monday, November 23rd. Frazier Life Sciences Acquisition Corp. II had issued 7,500,000 shares in its public offering on October 14th. The total size of the offering was $75,000,000 based on an initial share price of $10.00. During Frazier Life Sciences Acquisition Corp. II’s quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Frazier Life Sciences Acquisition Corp. II to a “hold” rating in a research note on Saturday, October 24th.

View Our Latest Analysis on Frazier Life Sciences Acquisition Corp. II

Frazier Life Sciences Acquisition Corp. II Price Performance

Shares of Frazier Life Sciences Acquisition Corp. II stock opened at $10.08 on Friday. Frazier Life Sciences Acquisition Corp. II has a 12-month low of $9.95 and a 12-month high of $10.63.

Insider Buying and Selling at Frazier Life Sciences Acquisition Corp. II

In other Frazier Life Sciences Acquisition Corp. II news, CEO Albert Cha purchased 300,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were acquired at an average cost of $10.00 per share, for a total transaction of $3,000,000.00. Following the completion of the purchase, the chief executive officer owned 300,000 shares of the company’s stock, valued at approximately $3,000,000. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Frazier Life Sciences Acquisition Corp. II Company Profile

(Get Free Report)

Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company (SPAC) formed to pursue a merger, asset acquisition, stock purchase, reorganization or similar business combination. Its stated focus is on businesses in the life sciences sector. As a SPAC, the company does not itself develop or sell medicines, medical devices or other products. Its role is to identify and combine with a target business, which would then operate as a public company. The company is associated with Frazier Life Sciences, the life sciences investment arm of Frazier Healthcare Partners.

See Also

Receive News & Ratings for Frazier Life Sciences Acquisition Corp. II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frazier Life Sciences Acquisition Corp. II and related companies with MarketBeat.com's FREE daily email newsletter.